Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Drug-Induced Hepatotoxicity

Pilin Francis  1 , Victor J. Navarro  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Drug-Induced Hepatotoxicity

Pilin Francis et al.
Free Books & Documents

Excerpt

Drug-induced hepatotoxicity or drug-induced liver injury (DILI) is an acute or chronic response to a natural or manufactured compound. DILI can be classified based on clinical presentation (hepatocellular, cholestatic, or mixed), mechanism of hepatotoxicity, or histological appearance from a liver biopsy. The true incidence is difficult to estimate, yet it has become the leading cause of acute liver failure (ALF) in the United States. The 2 mechanisms of hepatotoxicity are intrinsic, dose-dependent, and idiosyncratic, which is more unpredictable. Most cases of DILI are asymptomatic; however, the most common sign is jaundice. Laboratory tests in hepatocellular injury will have elevation in aminotransferases, while in cholestatic injury, alkaline phosphatase (ALP) is elevated. A liver biopsy is not mandatory for diagnosis but could exclude other causes of liver disease. Treatment begins with the removal of the offending agent, and the prognosis for recovery is usually favorable after discontinuation of the drug.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Pilin Francis declares no relevant financial relationships with ineligible companies.

Disclosure: Victor Navarro declares no relevant financial relationships with ineligible companies.

References

    1. Fisher K, Vuppalanchi R, Saxena R. Drug-Induced Liver Injury. Arch Pathol Lab Med. 2015 Jul;139(7):876-87. - PubMed
    1. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J, United States Drug Induced Liver Injury Network Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015 Jun;148(7):1340-52.e7. - PMC - PubMed
    1. Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond) 2016 Dec;16(Suppl 6):s104-s109. - PMC - PubMed
    1. Kuna L, Bozic I, Kizivat T, Bojanic K, Mrso M, Kralj E, Smolic R, Wu GY, Smolic M. Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives. Curr Drug Metab. 2018;19(10):830-838. - PMC - PubMed
    1. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ, Practice Parameters Committee of the American College of Gastroenterology ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014 Jul;109(7):950-66; quiz 967. - PubMed

Publication types

LinkOut - more resources